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troversial and timely, because it is possible your comments
may actually add some helpful and potentially beneficial
opinions and perspectives. For all of these reasons, I have
chosen to direct my remarks towards the subject of
endovascular repair of abdominal aortic aneurysm (AAA).
I believe it is an important subject and it is certainly a con-
troversial one. To me, it represents both the challenges
and opportunities that exist for our specialty as we enter a
new millennium. Indeed, the evolution of the treatment of
aortic aneurysm offers a fascinating window into the
remarkable progress that vascular surgery has made over
the last half of the 20th century.
A NEW MILLENNIUM
It was the best of times, it was the worst of times.
Charles Dickens, A Tale of Two Cities
As we enter a new millennium, we are truly in a period
of dramatic change and epochal transformation. As a
youngster, I recall futuristic books such as 1984 by George
Orwell or 2001: A Space Odyssey by Arthur C. Clarke. The
concepts and images in these works seemed so far off, yet
Big Brother and spacecraft Discovery are a reality now. In
this current “computer age” and “knowledge and service
society” we now live in, few would recognize the world into
which one’s parents were born. For example, in 1945 more
than 30% of all workers lived and worked on farms; today,
less that 2% do.1 The bygone era of the doctor’s black bag
and glass hypodermic needle has been replaced with com-
puted tomography (CT) scans, magnetic resonance imag-
ing, designer drugs, and high-tech magic bullets.
Vascular surgery has not escaped this revolutionary
change. Emblematic of our current age of technology,
new therapies, largely catheter-based, are challenging our
traditional “index” surgical procedures. We’ve grown
comfortable with such traditional open procedures, know
how to perform them, and know when they should be
done. In this new era, some have said that 40% to 70% of
these signature procedures will be replaced.2 In addition
to significantly altering accepted approaches and standard
I would like to thank you for the great privilege of
serving as the 27th president of the New England Society
for Vascular Surgery. Our society, the first regional vascu-
lar society in the nation, has a long and proud heritage of
accomplishment and contributions to our specialty, and
many leaders in our field have emerged from our ranks.
The New England Society for Vascular Surgery represents
all that is positive and valuable in a regional society. To be
elected by you, my friends and colleagues, to carry its ban-
ner is the highest honor one could wish for.
The chance to present a presidential address represents
an unparalleled opportunity to express one’s views with-
out constraints of scientific evidence or hard data.
However, with this unique occasion comes the difficulty
of selecting an appropriate and worthy topic. In making
such a choice, one usually becomes a scholar of past pres-
idential addresses and discovers several broad categories of
topics. These vary from scientific, historic, or socioeco-
nomic themes to political or even philosophical views of
the individual.
Although one hopes to say something learned and
profound, you discover that there is really no way to select
a truly new topic. It is usually recommended to say some-
thing meaningful but avoid too much philosophical over-
tones and to keep it brief without too many slides. The
best advice seems to be to make your selection a personal
one and talk about something that you know about and
are sincerely interested in. It also helps if the topic is con-
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procedures, the new technology crosses practice bound-
aries and is also the focus of intense entrepreneurial and
commercial activity. The impact of technology is change,
but with change often come conflict and anxiety.3
Endovascular AAA repair is currently a focal point for
conflict and anxiety that such changes have created in our
own specialty. Few topics are more controversial or of
more concern to all practitioners. This catheter-based,
image-guided technology has the potential to redefine tra-
ditional care of one of our specialty’s most common and
important surgical procedures.
As surgeons, we all make daily decisions regarding the
best treatment for our patients. We must determine
whether operative intervention is indicated, what proce-
dure would be best, and what should be the optimal tim-
ing. In reaching such often difficult decisions, we are all
familiar with being asked by patients and their families,
“What would you do if it were your father?” as if such a
statement would encourage us to make a better or more
thoughtful recommendation. Therefore, I’ve decided to
relate my observations and opinions on endoluminal AAA
repair in this framework.
Why is this important? AAA remains an important
problem. Approximately 200,000 new cases are diagnosed
each year, and 50,000 to 60,000 surgical AAA repairs are
performed. Ruptured AAA is responsible for approximately
15,000 deaths in the United States each year, making it the
14th leading cause of death in this country, similar in mag-
nitude to emphysema, renal disease, and homicide.4
It is clear that we are an aging society. From 1900 to
1996, life expectancy increased approximately 30 years,
from less than 50 years to almost 80, a stunning prolon-
gation of life of three decades. With age 65 as the usual
definition of an elderly person, by 2020 when current
baby boomers come of age, the elderly segment of our
society is expected to increase by 35%.5,6 The over-85 age
group is the fastest growing segment of the population in
our country. Indeed, the US Census Bureau estimates that
the number of people 100 years of age or older will
increase almost 30-fold, to more than 800,000 centenari-
ans by 2050.7 It is certain that our patients are getting
older, and some extremely old.
The impact of this is the certainty of more aneurysms,
because abundant data exist to show that the prevalence of
AAA and rupture risk increases sharply with advancing
age.8,9 One in 10 men older than 80 has some aneurysmal
change in his aorta.10 Besides aging, other factors must be
involved, because the incidence of small AAA has
increased almost 30-fold.11 Certainly, better diagnosis and
more frequent imaging studies are involved, but it appears
there has been a true increase in prevalence as well.12
Thus, it is certain that in coming years vascular surgeons
are going to deal with more patients with AAA in their
practice, many of whom are elderly and high risk. Several
estimates indicate a likely increase of 30% to 40% in
aneurysmal disease in a vascular division’s activities.6,13
It is also apparent to me that we are not currently
doing as well as we often think in treating patients with
AAA. Although elective mortality rates of only 1% to 5%
are reported in many high-volume institutional-based
studies,14 numerous population-based reports that are
more likely representative of the “real world” show mor-
tality rates in the 5% to 10% range even in contemporary
practice.15-18 Significant systemic complications occur in
at least 15% to 30% of patients,19-21 and morbidity and
mortality rates are recognized to substantially increase in
elderly patients or in those with significant pulmonary or
renal comorbidities.19,22 Recovery commonly takes several
months, and some elderly individuals never quite regain
their preoperative baseline status. In addition, many high-
risk patients are currently denied operative repair because
they are considered unlikely to survive the procedure.
Finally, it is well documented that we are making little
progress in improving results of ruptured AAA. Despite
more frequent elective operations, the incidence and poor
outcome of ruptured AAA have remained virtually
unchanged over the past 20 years.23 Therefore, the possi-
bility of a less invasive method of treatment that might
reduce risk, provide other possible patient benefits includ-
ing quicker recovery, and extend the chance of successful
repair to a greater number of patients has tremendous
appeal to patients and physicians alike.
If my father had an AAA, the first thing I would tell
him would be to seriously consider endovascular repair.
It’s a real treatment possibility, and not a fad likely to dis-
appear like laser angioplasty.
A LOOK BACK
The farther backward you can look, the farther forward you
are likely to see.
Winston Churchill24
The tides of technology are strong, and lessons of the
past slip quickly behind us.25 The evolution of AAA treat-
ment is both fascinating and potentially instructive.
Although recognized in Egyptian mummies and described
by other early physicians, the actual treatment of aneurysms
was not attempted until many centuries later. The focus of
early intervention was ligation or banding, but results were
usually poor because of the failure to totally exclude the
AAA and prevent its rupture resulting from insecure oblit-
eration of proximal or distal flow, collateral blood flow into
the sac, or erosion of bands or ligatures through the aortic
neck with resultant fatal hemorrhage.24 Does this sound at
all familiar to some of the current potential difficulties and
shortcomings of endovascular repair?
Other early efforts aimed at limiting AAA expansion and
rupture included wrapping the aneurysm with materials such
as cellophane, thereby hoping to limit growth or disruption
by both mechanical restraint and an intense induced peri-
aneurysmal inflammatory response and subsequent fibrosis.
Perhaps the best known patient treated in this fashion was
Albert Einstein, then the world’s most famous and out-
standing scientist, who underwent cellophane wrapping for
a “large” and possibly symptomatic AAA in 1948, just
before the dawn of true AAA graft repair. Einstein would
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survive 61⁄2 years before succumbing in 1955 to fatal AAA
rupture at age 76, rejecting recommended urgent surgical
treatment at that time. Einstein said, “I want to go when I
want. It is tasteless to prolong life artificially, I have done my
share, it is time to go. I will do it elegantly.”26 Was the bet-
ter than anticipated 61⁄2-year survival after his wrapping pro-
cedure just good luck, or did the treatment itself favorably
modify the natural history of that aneurysm? Should his pro-
cedure be judged a failure, or in fact, was it in many ways
quite successful? Again, there are similarities to dilemmas
now encountered in evaluating the place of stent graft repair.
The possible advantages of working “within” the vas-
cular system itself were recognized early. The attempted
treatment of aneurysm with endoluminal wiring was prac-
ticed for many years.27,28 Although generally ineffective in
this regard, it is certainly a prelude to intraluminal coiling
and embolization of aneurysmal vessels in use today.
Certainly the endoaneurysmorrhaphy principles of Matas,29
culminating in the endoaneurysmal technique of graft
implantation first described by Creech,30 are commonly
applied as standard practice today. The desire to reduce
morbidity and mortality by working endoluminally led to
the first catheter-based treatment of vascular disease by
Fogarty in 1963 and ultimately to the initial catheter-based
treatments of AAA with transfemoral endograft repair.31,32
Few would disagree that progress in modern aortic
surgery would not have been possible without the develop-
ment of clinically applicable prosthetic arterial substitutes.33
Rigid tubes had been tried to replace diseased blood vessels,
but these failed early because of thrombosis or erosion.34
Homograft insertion represented an early breakthrough,
but these conduits were soon noted to undergo significant
biologic degeneration and have additional problems of pro-
curement and availability. The era of modern vascular
surgery began with Voorhees and his development of
Dacron grafts in the early 1950s. Like Fogarty, Voorhees
was a surgical resident when he began his innovative semi-
nal work. Although his first efforts at fashioning an arterial
conduit in the animal laboratory, created at first on his
wife’s sewing machine from a silk handkerchief, and later
using Vinyon-N, a fabric used for making spinnaker sails,
were only partially successful, continued work by him and
his colleagues ultimately led to development of reliable
prosthetic grafts as we now know them.35 Is there a lesson
to be learned here? Perhaps one should not condemn or
abandon a new concept of treatment or a newly developed
device simply because of problems and failures of initial pro-
totypes and early first-generation versions.
WHAT IS SUCCESS?
It is the patient rather than the case which requires treatment.
Robert Tuttle Morris, Doctors Versus Folks
At the heart of the current uncertainty about the
proper role of endovascular AAA repair is the debate
regarding what should constitute appropriate and mean-
ingful outcome criteria. In other words, how should we
define success?
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Endoluminal repair is criticized mainly for two per-
ceived shortcomings: endoleak and inferior durability.
Failure to completely exclude the AAA from the circula-
tion, as determined with postimplant radiologic studies,
has been termed endoleak.36 To be sure, endoleaks are
not infrequent and are reported in 15% to 52% of early
postimplant CT scans in various series.37-41 In a meta-
analysis of 23 publications in which 1118 patients are
described with successful implantation of AAA endo-
grafts, Schurink et al42 determined an average endoleak
rate of 24%. It is commonly believed that persistent
endoleak represents a clinical failure of the procedure, but
I’m not certain this is valid.
A second criticism of endoluminal repair is its poten-
tially inferior durability as compared with conventional
open surgery. Such concerns have been voiced with
increasing frequency within the recent time period as
midterm experience has accumulated and documented
instances of device structural failure, migration, late
endoleaks, limb thrombosis, and other problems including
rupture.43-50 However, further experience has also clearly
showed that many, if not most, such difficulties except
rupture may be successfully treated with secondary
catheter-based interventions, and that open operations are
usually unnecessary.41,51 Are such problems, therefore,
appropriate justification for condemnation of the method?
I would suggest to my father that he consider some-
what different and more pragmatic outcome criteria for
success (Table I) than those commonly proposed.52
Certainly no patient wishes to not survive the procedure,
so mortality risk is a legitimate concern. I would naturally
focus attention on what is, after all, the goal of any treat-
ment for AAA: to prevent aneurysm rupture. Because of
the well-established relationship of size and rupture risk,
limiting AAA growth is a natural corollary of this goal.
Finally, a patient undergoing endovascular repair would
naturally wish to avoid the need for conversion to open
repair, either acutely or during the later follow-up interval,
especially in view of the increased morbidity and mortality
of conversions documented in many reports.53,54
Notably absent in these objectives is endoleak status,
which in my mind is generally overemphasized in evaluat-
ing the efficacy of endoluminal repair. Although endoleaks
may frequently be correlated with subsequent AAA expan-
sion and rupture risk, this is often an uncertain relation-
ship. Some series have shown that a substantial number of
AAAs stay unchanged in maximal diameter, or even
decrease in size, despite demonstrated endoleak.41,55-59
Type II (branch) endoleaks, by far the most common vari-
ety in all series, are thought by some investigators to not
Table I. Criteria for clinical “success”
No perioperative mortality
No AAA rupture
No AAA growth (≥ 5 mm)
No conversions/explant
result in AAA expansion or rupture in most cases.60,61 In
addition, slower than anticipated AAA growth in some
patients with persistent leak suggests some beneficial
hemodynamic response from endoluminal repair even in
this group.62 Other authorities stress that AAA enlarge-
ment or rupture may occur without demonstrable
endoleak, likely by means of pressure transmission
through intrasac thrombus—a concept referred to as
endotension.63,64 Thus, endoleak per se may be a poor
marker for the risk of subsequent AAA enlargement or
rupture, and therefore, an inaccurate determinant of a
clinically “successful” outcome. Indeed, the clinical signif-
icance of endoleaks and their impact on the natural history
of an aneurysm remains uncertain and poorly understood
at present. Until we can accurately measure actual pressure
within the AAA sac after endograft repair, changes in AAA
maximal diameter (or better still AAA sac volume) may
well be a better surrogate for evaluating treatment efficacy
rather than endoleak.41
It is now evident that many late problems occurring in
endografts and affecting the durability of the repairs are a
consequence of morphologic changes in the treated AAA
sac and transmittal of these forces and dimensional changes
to the endograft device within the aneurysm lumen.65-67
Thus, modular component separation, proximal or distal
device migration or dislodgment, limb kinks or occlusions,
and other difficulties are usually detected in AAA sacs that
have shrunken the most. They are what I refer to as the
“paradox of success,” difficulties occurring as a result of
achieving the very objective of the original procedure:
exclusion and shrinkage of the AAA. I’d emphasize to my
father that most of these alterations can be corrected by
additional adjunctive catheter-based procedures and point
out the importance of “secondary outcome success,”
which is often achievable. In my mind, such secondary pro-
cedures are not a major liability as long as they are success-
ful. We readily accept the concept of “assisted patency” in
vascular bypass grafts, so why not apply these concepts to
endografts? In addition, the parallels to coronary angio-
plasty are obvious. Even though it is well documented that
up to 30% to 40% of patients treated with percutaneous
transluminal coronary angioplasty may require additional
catheter procedures during follow-up, this is generally well
accepted by most patients if the ultimate outcome is com-
petitive with major surgical revascularization and the much
more invasive treatment can be avoided.68
HOW ARE WE DOING?
It usually requires a considerable time to determine with cer-
tainty the virtues of a new method of a treatment and usually
longer still to ascertain the harmful effects.
Alfred Blaylock, Principles of Surgical Care
In advising my father, I’d certainly lean heavily on our
own experience with endovascular AAA repair at
Massachusetts General Hospital. We’ve now been doing
such procedures for more than 61⁄2 years since our first
endograft in January 1994. Incidentally, this patient, an
83-year-old gentleman at the time of endovascular repair
of his 6-cm AAA, just recently died of cancer at age 90. I’d
say this was a good result, and the perfect role for these
procedures.
From January 1994 through August 2000, we
implanted 391 stent grafts. Of these, 334 were for primary
repair of AAAs (Table II). A total of 277 (83%) of these
patients were male, with average age of 75 years (range,
44-93). Mean maximal diameter of the AAA was 5.78 cm.
As shown in Table III, five different varieties of commer-
cial devices and 101 custom-fabricated devices were used
in repairs, as previously described.69,70 Graft configura-
tions included 72.4% bifurcated, 18.3% aorto-uniiliac with
femorofemoral bypass, and 9.3% tube endografts.
There were four (1.2%) perioperative deaths; two
patients with a history of significant coronary artery dis-
ease died of an acute myocardial infarction, both occur-
ring on the second postoperative day. One high-risk
patient died 10 days after endograft repair, after a complex
course and multiorgan failure that was likely a result of dif-
fuse atheroemboli. The final death occurred in a patient at
home, 5 days after endoluminal repair of a large, probably
symptomatic, AAA. A possible proximal endoleak was sus-
pected on predischarge CT scan. Although no post-
mortem examination was performed, clinical history and
symptoms suggested probable rupture of his AAA.
The average length of stay has been 2.4 days. Other
early benefits of endoluminal repair that have been well
documented in many series, including shorter operating
time, essential elimination of intensive care unit (ICU)
stays, and substantial reductions in blood loss and transfu-
sion requirement, were well illustrated in our series. In
recent years, almost all procedures have been performed
with patients under epidural anesthesia alone.
Four (1.2%) patients required intraprocedural conver-
sion, two because of iliac access problems and two as a
result of technical errors in deployment. The remaining
330 (98.8%) grafts were successfully implanted. Six (1.7%)
patients have required late conversion and graft explanta-
tion. Three of these patients were converted because of
progressive AAA sac enlargement; all of these patients had
persistent Type I attachment endoleaks. One patient pre-
JOURNAL OF VASCULAR SURGERY
1142 Brewster June 2001
Table II. Endovascular AAA repair, 1994-2000, 334
total cases
Male 83%
Mean age 74.4 y (range, 44-93)
Mean AAA diameter 5.78 cm
Technically successful implants 98.8%
Perioperative mortality 1.2%
Mean length of stay 2.4 d
Secondary endovascular procedures 10.5%
Conversions
Acute 1.2%
Remote 1.7%
AAA growth (≥ 5 mm) 5.8%
AAA rupture 0.5%
sented acutely with symptoms of back pain and suspected
rupture. Studies revealed a new Type III endoleak and
acute reexpansion of her AAA, which had decreased 1 cm
in maximal diameter over the 6 months since implanta-
tion. At explant, the leak was found to be due to a hole in
the endograft presumably as a result of fabric erosion. One
patient underwent explantation at 2 years because of infec-
tion of his endograft, resulting from hematogenous seed-
ing from a septic intravenous port device. The final patient
presented with rupture of his AAA 31⁄2 years after endo-
graft repair. Six follow-up CT scans had not shown
endoleak, and his AAA had shrunken more than 1.5 cm in
maximal diameter. At explant, the distal tube endograft
attachment was found acutely disrupted. The patient sur-
vived and is doing well currently. With the other case of
presumptive rupture, two (0.5%) patients have experi-
enced rupture after endograft AAA repair over our 61⁄2-
year experience.
Early endoleaks were detected at discharge in 32% of
patients, 71% being Type II and 29% Type I. Sixty-three
percent of these early endoleaks closed spontaneously.
Twelve percent of patients had persistent leaks. Late
remote endoleaks were detected in an additional 6% of
patients.
Thirty-five (10.5%) patients have required 42 sec-
ondary procedures to treat persistent endoleaks or correct
other late problems affecting the endograft implant (Table
IV). Overall, AAA sac maximal diameter decreased or
remained unchanged in size in 94.2% of patients. Sac
enlargement of 5 mm or more was noted in 5.8% of
patients.
CROSSROADS
Two roads diverged in a yellow wood,
And sorry I could not travel both
And be one traveler, long I stood
And looked down one as far as I could
To where it bent in the undergrowth;
I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I—
I took the one less traveled by,
And that has made all the difference.*
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Endovascular AAA repair can no longer be regarded as
a new, innovative, “experimental” procedure. As illus-
trated by our results and numerous other reports, the fea-
sibility and generally good early efficacy in many patients
have been well documented.37,38,40,46,69,71-76 In my mind,
the most impressive data regarding efficacy have been the
success of the procedure in realizing its primary goals: lim-
iting aneurysm growth and preventing rupture. As shown
by our data, only 5.8% of AAA were noted to increase 5
mm or more, and only 0.5% ruptured. One must remem-
ber that the best available data on the natural history of
untreated AAA indicate an 11% annual rupture risk of
AAA in the 5.0- to 5.9-cm size range (our mean, 5.78 cm)
and average anticipated growth rates of approximately
10% (5-6 mm) per year.77-80 Similar success with control
of AAA growth, low rates of conversion, and low inci-
dences of rupture have been reported in the 1- and 2-year
data from the EVT/Guidant Ancure, Boston Scientific
Vanguard, and Medtronic AneuRx US trials.41,54,76,81,82
However, at present we simply do not have sufficient
long-term data to answer questions and concerns about
durability. Nevertheless, the importance of durability has
been overemphasized to some degree in my mind. At least
in my practice, most patients with clinically significant
aneurysms are quite old, and most have overt comorbid
chronic medical conditions. As shown in Hallett’s popula-
tion-based study,11 average 5-year survival after open
repair of large (> 5 cm) aneurysms was only 60%, with
most patients dying of myocardial infarction. Vascular
surgery has been called “the surgery of ruins,” and we
must remember that most of our procedures are palliative
in nature. We seem to readily accept failure rates of 20% to
40% at 5 years for femoropopliteal bypass and similar pro-
cedures. Should endografts necessarily be held to a higher
standard?
It is apparent that we are at a crossroads, and which
path my father should take is uncertain. The initial wave of
excitement and promise has tended to shift toward con-
Table III. Endograft devices
EVT Vanguard Gore Aneurx Zenith Custom Total
Tube 17 8 — — — 6 31 (9%)
Bifurcated 37 29 44 73 2 57 242 (73%)
Aorto-uniiliac 23 — — — — 38 61 (18%)
Total 77 37 44 73 2 101 334
Table IV. Secondary endovascular procedures
Intervention No. of procedures
Balloon angioplasty (PTA) 6
PTA with stenting 12
Embolizations 14
Additional stent grafts 7
Thrombolysis 3
PTA, Percutaneous transluminal angioplasty.
*Excerpt from “The Road Not Taken” by Robert Frost from
THE POETRY OF ROBERT FROST edited by Edward
Connery Lathem, published by Henry Holt and Company,
New York, LLC.
cern or criticism.83 This is likely true of all new procedures
or methods. As in many choices, the decision is currently
a “trade-off”; the patients will benefit in clear-cut ways by
opting for the less invasive procedure, but in choosing this
road must accept the consequences of a less certain repair,
higher rate of reintervention, and need for probable life-
long follow-up. I would make certain my father under-
stood these issues and options. When advised with the best
estimates we can currently provide regarding all of these
possibilities and outcomes, I suspect he will be like the
overwhelming majority of patients with AAA I have eval-
uated and advised over the past 7 years. That is, if he has
suitable anatomy, he’ll choose the endograft pathway and
willingly accept the baggage this choice dictates that he
must carry on this road.
CAVEATS AND CAUTIONS
The essence of wisdom is the ability to make the right deci-
sion on the basis of inadequate evidence.
Alan Gregg
I’d certainly remind my father that it is absolutely
essential that he have suitable anatomy to consider endo-
luminal repair, and that this has been carefully studied and
appropriately evaluated. Endograft repair is driven by
anatomy, and established criteria should not be pushed
too far. Not every patient is an appropriate candidate.
Overzealous application invites technical complications,
poor results, and ultimately conversion procedures with
their recognized increase in morbidity and mortality.84-86
If my father had a small (< 4.5 cm) AAA, I’d urge him
to continue a policy of “watchful waiting.” I simply don’t
think we have enough data or experience presently to jus-
tify changing existing size thresholds or other indications
for repair.80 It is not yet clear that a “preemptive” strike
against a small AAA will favorably alter the natural history
of the AAA or that the device will function reliably long
enough to do so.
Finally, if my father did elect to undergo endovascular
repair, I’d certainly urge him to go to a surgeon and cen-
ter with sufficient experience in these procedures. The
data showing correlation of both surgeon and hospital vol-
ume, training, and experience with improved outcome in
open AAA procedures are really quite compelling.87-89 If
“practice makes perfect” for traditional surgical proce-
dures we all learn during 5 to 7 years of residency training
and fellowship, surely this is the case for endoluminal ther-
apies that surgeons are much less acquainted with. The
skill sets for many elements of the procedure, including
on-line interpretation of fluoroscopic images and complex
catheter manipulations, are not familiar to most vascular
surgeons. Despite the beguiling simplicity of the proce-
dures in concept, they often prove complex, and there is
indeed a steep learning curve as shown in many studies.90
It is clear that technical problems and resultant complica-
tions are much more common in the early stages of the
learning curve.91,92 The parallel to laparoscopic cholecys-
tectomy in its early stages is quite apparent.93 New tech-
nology poses a challenge, because new technology must
be learned, practiced, and mastered. Competency also
extends to adequate facilities, equipment, and support
personnel.
In short, I don’t think it’s likely or even appropriate to
expect that these procedures will be done at all hospitals
by all vascular surgeons. The potential benefits of region-
alizing selected surgical procedures have been recognized
for at least two decades. Large population-based studies
have consistently demonstrated better outcomes at high-
volume centers, be it for vascular surgery, cardiac surgery,
major cancer resections, or other high-risk procedures.94
Hospital volume seems an even stronger predictor than
individual surgeon volume, because hospital volume is a
proxy for more components of perioperative care such as
support staff, equipment, technology, and ICU care.
GLIMPSES OF THE FUTURE
The future ain’t what it used to be.
Yogi Berra
There is no doubt in my mind that endovascular
aneurysm repair is here to stay in some regard. No doubt
further advances in technology will continue to widen
application of the method and produce more favorable
outcomes, as seen already with first- and second-genera-
tion devices.95 Improved devices will also likely be better
able to cope with changing AAA sac morphology, a major
mode of late failures and complications currently.
Suprarenal fixation may allow successful treatment of
more patients with short infrarenal necks, and methods of
endoluminal stapling promise to improve security and reli-
ability at endograft attachment sites. Branched endografts
may be devised that will allow treatment of juxtarenal AAA
or perhaps even thoracoabdominal aneurysms. The advan-
tages of less invasive laparoscopic approaches may be
applied to management of persistent Type I or II
endoleaks by means of banding or clipping. The accuracy
of follow-up of the efficacy of endograft AAA repairs will
surely improve as better and easier methods of measuring
actual AAA sac volume, and perhaps even determining
intrasac pressure, are developed.
This method will likely be the preferred technique for
high-risk patients.69,80,96 In addition, endograft repair
offers an appealing and expeditious solution to other dif-
ficult problems including aneurysm patients with “hostile”
abdomens, recurrent pararenal true aneurysms or anasto-
motic false aneurysm formation, problems relating to
degenerated grafts, or inflammatory AAA. Whether it will
or should replace open repair in younger low-risk patients
remains to be seen.97-99 I would say not yet. However, I
think current results are competitive enough that we have
justification, if not an obligation, to at least offer the pos-
sibilities of endoluminal repair to such patients, to inform
them of the advantages and limitations as we best know
them currently and then let patients determine which road
they would choose to travel. There is growing recognition
that a component of “quality care” is responsiveness to
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preferences and values of the consumers of health care ser-
vices, especially the individual patient.100
A major difficulty remains training surgeons to do the
procedures with appropriate skill and competency. Our
vascular training programs will change and adapt, and I
believe will eventually meet the challenges of changing
patterns of practice.101 A bigger problem in my mind
exists for present practitioners. How to gain adequate
training and experience for this group is a difficult issue
and a good topic for someone else’s future presidential
address. Weekend minicourses simply will not suffice.
Some surgeons will simply forge ahead and gain expertise
as they go, probably at some expense to their patients.
Some will be aided by interventional colleagues in other
specialties, if they are fortunate enough to have these rela-
tionships in their own institutions. Some will accept the
difficulties of a 3- to 6-month period away from their prac-
tices and do a “preceptorship” at a growing number of
institutions that are doing adequate volumes of endovas-
cular procedures and willing to offer such training oppor-
tunities. Perhaps the most likely solution is a reverse in the
usual pattern of training: have recent graduates of con-
temporary training programs teach these skills to their
more senior partners and colleagues in a group or a par-
ticular hospital.
Alternatively, a surgeon may become an integral part
of a multidisciplinary team at his or her hospital.102 In my
mind, this is perhaps the ideal approach and likely to pro-
duce the best outcomes for the patient. All involved learn
as they go, and professional growth and satisfaction result
for all parties. This may be a utopian ideal, however, and
not realistically achievable in all environments. As with
many things, financial obstacles may be paramount.
I remain concerned regarding the high cost of the
devices currently. We recognize the cost savings resulting
from shorter procedure times, no ICU utilization, and
dramatic reductions in length of stay. However, it seems
clear that these savings are all lost and then some with the
addition of the expense of the device and other disposables
involved in the procedure and that endoluminal repair is
currently more costly than open surgery.103-105 If this con-
tinues, the adverse economic impact on institutions may
well limit widespread application of this technology. I
believe manufacturers must recognize this and make
responsible pricing decisions.
Certainly, we must continue to acquire further knowl-
edge on the long-term behavior of such grafts and their
benefit in favorably altering the natural history of aneurys-
mal disease. Although randomized studies might be
ideal,97 I doubt that we can achieve this. In my experience,
if patients have suitable anatomy for endoluminal therapy,
most simply will not allow their fate to be “pulled out of
a hat” by the randomization process. In addition, the pace
of technologic advances often makes outcome of random-
ized studies outdated by the time they’re finished.83,95
Endovascular repair has been a new development in
my professional life, and I have found it exceedingly grat-
ifying to help many patients solve this dangerous problem
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in their lives with such truly dramatic reductions in mor-
bidity and quicker recoveries. I firmly believe vascular sur-
geons will maintain a leadership position in the treatment
of aortic aneurysms, as we always have; this is simply
another way that may be best for certain patients. Rather
than a threat, I believe we should remember that in every
challenge there is an opportunity. I’m sure my father
would agree.
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